Semaglutide
5mg
Semaglutide activates GLP-1 receptors to regulate appetite and glucose, with outcomes documented across more than 17,000 trial participants. It sustains an average 15% body weight reduction past two years and is the first compound in its class shown to reduce major cardiovascular events in a controlled trial.
Included free with every order
Bacteriostatic reconstitution solution and sterile dosing needles are included, a $30+ value, always included. Most suppliers charge extra. We never do.
Purity
99.4%
Form
Lyophilized powder
Storage
-20°C
Includes
Solution + needles
Research use only. Not for human consumption. Need help reconstituting? Use our dosing calculator.
Research Outcomes
What The Clinical Data Shows
Based on published peer-reviewed literature. Not medical claims.
15%
Average body weight reduction across STEP trials
20%
Reduction in major cardiovascular events, SELECT trial
17,600+
Total participants across all major published trials
Food preference shift. Neuroimaging showed reduced activation of brain reward centers in response to high-calorie food cues, indicating a shift in food preference rather than simple appetite suppression.
Cardiovascular outcome. The SELECT trial (17,604 participants with cardiovascular disease, no diabetes) showed a 20% reduction in heart attack, stroke, and cardiovascular death, independent of weight loss.
Sustained at two years. STEP 5 documented 15.2% weight loss maintained at 104 weeks, suggesting a shift in the body's weight set point rather than temporary suppression.
Secondary outcomes. Sleep apnea events fell by up to 61% in one trial arm, with measurable improvements in knee pain and physical function beyond what weight loss predicts.
Research context. All findings are from peer-reviewed literature. Not FDA-approved. Sold for research purposes only. Results in research settings may vary. Not medical advice.